Potential therapeutic effect of intravesical botulinum toxin typeA on bladder pain syndrome/interstitial cystitis

International Journal of Urology

Volumn 21, Issue S1, 2014, Pages 49-55

  Jhang, Jia Fong ^a   Jiang, Yuan Hong ^a   Kuo, Hann Chorng ^a  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Bladder pain syndrome; Botulinum toxin; Interstitial cystitis

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; MUSCLE RELAXANT AGENT;

BLADDER CAPACITY; BLADDER FUNCTION; CYSTALGIA; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INJECTION SITE; INTERSTITIAL CYSTITIS; NEUROMUSCULAR SYNAPSE; NOCTURIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REPEAT PROCEDURE; REVIEW; THERAPY EFFECT; ULCER; URINE RETENTION; BLADDER; COMPLICATION; CYSTITIS, INTERSTITIAL; DRUG EFFECTS; INTRAVESICAL DRUG ADMINISTRATION; LOWER URINARY TRACT SYMPTOMS; MICROBIOLOGY; PATHOPHYSIOLOGY; PELVIC PAIN; PSYCHOLOGY; QUALITY OF LIFE; TREATMENT OUTCOME; URINE;

ADMINISTRATION, INTRAVESICAL; BOTULINUM TOXINS, TYPE A; CYSTITIS, INTERSTITIAL; HUMANS; LOWER URINARY TRACT SYMPTOMS; NEUROMUSCULAR AGENTS; PELVIC PAIN; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER; URINE;

EID: 84899894268     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12317     Document Type: Review

References (70)

1. Hanno PM, Burks DA, Clemens JQ etal. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J. Urol. 2011; 185: 2162-2170.
2. NIDDK workshop of interstitial cystitis. Besthesda, MA, 28-29 August 1987.
3. Homma Y, Ueda T, Tomoe H etal. Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int. J. Urol. 2009; 16: 597-615.
4. O'leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology 1997; 49: 58-63.
5. Mayer R. Interstitial cystitis pathogenesis and treatment. Curr. Opin. Infect. Dis. 2007; 20: 77-82.
6. Nazif O, Teichman JM, Gebhart GF. Neural upregulation in interstitial cystitis. Urology 2007; 69: 24-33.
7. Sant GR, Kempuraj D, Marchand JE, Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 2007; 69: 34-40.
8. van de Merwe JP, Yamada T, Sakamoto Y. Systemic aspects of interstitial cystitis, immunology and linkage with autoimmune disorders. Int. J. Urol. 2003; 10 (Suppl): S35-38.
9. Erickson DR, Kunselman AR, Bentley CM etal. Changes in urine markers and symptoms after bladder distention for interstitial cystitis. J. Urol. 2007; 177: 556-560.
10. Marinkovic SP, Moldwin R, Gillen LM, Stanton SL. The management of interstitial cystitis or painful bladder syndrome in women. BMJ 2009; 339: 337-342.
11. Onwude JL. What is the most effective treatment of interstitial cystitis? BMJ 2008; 338: 350-351.
12. Rapp DE, Turk KW, Bales GT, Cook SP. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J. Urol. 2006; 175: 1138-1142.
13. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain response in rats. J. Urol. 2004; 172: 1529-1532.
14. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. 1988; 39: 919-922.
15. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 2004; 64: 871-875.
16. Rosamilia A, Igawa Y, Higashi S. Pathology of interstitial cystitis. Int. J. Urol. 2003; 10 (Suppl): S11-15.
17. Bouchelouche K, Nordling J. Recent developments in the management of interstitial cystitis. Curr. Opin. Urol. 2003; 13: 309-313.
18. Shie JH, Liu HT, Kuo HC. Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis/painful bladder syndrome. Urology 2012; 79: 484e7-1.
19. Christmas TJ, Rode J, Chapple CR, Milroy EJ, Turner-Warwick RT. Nerve fibre proliferation in interstitial cystitis. Virchows Arch. A. Pathol Anat Histopathol. 1990; 416: 447-451.
20. Lundeberg T, Liedberg H, Nordling L, Theodorsson E, Owzarski A, Ekman P. Interstitial cystitis: correlation with nerve fibres, mast cells and histamine. Br. J. Urol. 1993; 71: 427-429.
21. Lakhan SE, Kirchgessner A. Neuroinflammation in inflammatory bowel disease. J. Neuroinflammation 2010; 7: 37.
22. Li WW, Guo TZ, Liang DY, Sun Y, Kingery WS, Clark JD. Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. Anesthesiology 2012; 116: 882-895.
23. Pang X, Marchand J, Sant GR, Kream RM, Theoharides TC. Increased number of substance P positive nerve fibres in interstitial cystitis. Br. J. Urol. 1995; 75: 744-750.
24. Yamada T, Nishimura M, Mita H. Increased number of apoptotic endothelial cells in bladder of interstitial cystitis patients. World J. Urol. 2007; 25: 407-413.
25. Shie JH, Kuo HC. Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU Int. 2011; 108: E136-141.
26. Shea VK, Cai R, Crepps B etal. Sensory fibers of the pelvic nerve innervating the rat's urinary bladder. J. Neurophysiol. 2000; 84: 1924-1933.
27. Burnstock G. Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. J. Anat. 1999; 194: 335-342.
28. Rong W, Spyer M, Burnstock G. Activation and sensitisation of low and high threshold afferent fibres mediated by P2X receptors in the mouse urinary bladder. J. Physiol. 2002; 541: 591-600.
29. Sun Y, Chai TC. Up-regulation of P2X3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis. J. Urol. 2004; 171: 448-452.
30. Cervero F. Sensory innervation of the viscera: peripheral basis of visceral pain. Physiol. Rev. 1994; 74: 95-138.
31. Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J. Urol. 1999; 162: 3-11.
32. Watanabe T, Yokoyama T, Sasaki K, Nozaki K, Ozawa H, Kumon H. Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity. Int. J. Urol. 2004; 11: 200-205.
33. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816-824.
34. Homma Y, Nomiya A, Tagaya M etal. Increased mRNA expression of genes involved in pronociceptive inflammatory reactions in bladder tissue of interstitial cystitis. J. Urol. 2013; 190: 1925-1931.
35. Sculptoreanu A, de Groat WC, Buffington CA, Birder LA. Protein kinase C contributes to abnormal capsaicin responses in DRG neurons from cats with feline interstitial cystitis. Neurosci. Lett. 2005; 381: 42-46.
36. Erbguth FJ. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov. Disord. 2004; 19 (Suppl 8): S2-6.
37. Sakaguchi G, Kozaki S, Ohishi I. Structure and function of botulinum toxins. In: Alouf JE, Fehrenbach FJ, Freer JH, Jeljaszewicz J (eds). Bacterial Protein Toxins. Academic Press, London, 1984; 435-443.
38. Yokoyama T, Chancellor MB, Oguma K etal. Botulinum toxin type A for the treatment of lower urinary tract disorders. Int. J. Urol. 2012; 19: 202-215.
39. Schiavo G, Rossetto O, Santucci A etal. Botulinum neurotoxins are zink proteins. J. Biol. Chem. 1992; 267: 23479-23483.
40. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N. Engl. J. Med. 1991; 324: 1186-1194.
41. Dong M, Yeh F, Tepp WH etal. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312: 592-596.
42. Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxoid. Annu. Rev. Pharmacol. Toxicol. 1986; 26: 427-453.
43. Smith CP, Boone TB, de Groat WC etal. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res. Bull. 2003; 61: 165-171.
44. Smith CP, Gangitano DA, Munoz A etal. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem. Int. 2008; 52: 1068-1075.
45. Lucioni A, Bales GT, Lotan TL, Mcgehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute and chronic inflammation. BJU Int. 2008; 101: 366-370.
46. Lee BJ, Jeong JH, Wang SG, Lee JC, Goh EK, Kim HW. Effect of botulinum toxin type a on a rat surgical wound model. Clin. Exp. Otorhinolaryngol. 2009; 2: 20-27.
47. Kuo HC. Preliminary results of suburothelial injection of botulinum A toxin in the treatment of chronic interstitial cystitis. Urol. Int. 2005; 75: 170-174.
48. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur. Urol. 2006; 49: 704-709.
49. Ramsay AK, Small DR, Conn IG. Intravesical botulinum toxin type A in chronic interstitial cystitis: results of a pilot study. Surgeon 2007; 5: 331-333.
50. Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year follow up. J. Urol. 2008; 179: 1031-1034.
51. Giannantoni A, Cagini R, Del Zingaro M etal. Botulinum a toxin intravesical injections for painful bladder syndrome: impact upon pain, psychological functioning and quality of life. Curr. Drug Deliv. 2010; 7: 442-446.
52. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009; 104: 657-661.
53. El-Bahnasy AE, Farahat YA, El-Bendary M etal. A randomized controlled trial of bacillus Calmette-Guerin and botulinum toxin-A for the treatment of refractory interstitial cystitis. UroToday Int J. 2009; 2: 2-2. doi:10.3834/uij.1944-5784.2008.12.06.
54. Chung SD, Kuo YC, Kuo HC. Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Physician 2012; 15: 197-202.
55. Giannantoni A, Mearini E, Del Zingaro M, Proietti S, Porena M. Two-year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrome. Curr. Drug Deliv. 2010; 7: 1-4.
56. Pinto R, Lopes T, Silva J etal. Clinical response to intra-trigonal Onabotulinum toxin A injections is not related to the presence of ulcers in Bladder Pain Syndrome/Interstitial Cystitis patient. 2013 AUA abstract.
57. Gottsch HP, Miller JL, Yang CC, Berger RE. A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome. Neurourol. Urodyn. 2011; 30: 93-96.
58. Kuo HC. Repeated onabotulinumtoxin-A injections provide better results than single injection in treatment of painful bladder syndrome. Pain Physician 2013; 16: E15-E23.
59. Nigro DA, Wein AJ, Foy M etal. Association among cystoscopic and urodynamic findings for women enrolled in the Interstitial Cystitis Data Base (ICDB) Study. Urology 1997; 49: 86-92.
60. van de Merwe JP, Nordling J, Bouchelouche P etal. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur. Urol. 2008; 53: 60-67.
61. Koziol JA, Adams HP, Frutas A. Discrimination between the ulcerous and the nonulcerous forms of interstitial cystitis by noninvasive findings. J. Urol. 1996; 155: 87-90.
62. Tomaszewski JE, Landi JR, Russack V etal. Interstitial Cystitis Database Study Group. Biopsy features are associated with primary symptoms in interstitial cystitis: results from the interstitial cystitis database study. Urology 2001; 57: 67-81.
63. Peters KM, Killinger KA, Mounayer MH, Boura JA. Are ulcerative and nonulcerative Interstitial cystitis/painful bladder syndrome 2 distinct diseases? A study of coexisting conditions. Urology 2011; 78: 301-308.
64. Lee CL, Kuo HC. Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis. Pain Physician 2013; 16: 109-116.
65. Pinto R, Lopes T, Frias B etal. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur. Urol. 2010; 58: 360-365.
66. Tuttle JB, Steers WD, Albo M etal. Neural input regulates tissue NGF and growth of the adult urinary bladder. J. Auton. Nerv. Syst. 1994; 49: 147-158.
67. Dupont MC, Spitsberegen JM, Kim KB etal. Histological and neurotrophic changes triggered by varying models of bladder inflammation. J. Urol. 2001; 166: 1111-1118.
68. Okragly AJ, Niles AL, Saban R etal. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J. Urol. 1999; 161: 438-441.
69. Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 2007; 70: 463-468.
70. Shie JH, Liu HT, Wang YS, Kuo HC. Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome. BJU Int. 2013; 111: 638-646.